Business Context and Reporting Period
This Form 8-K is a current report filed by Novelos Therapeutics, Inc. (not Cellectar Biosciences, Inc.) on December 17, 2007. The filing addresses Item 5.02 regarding the appointment of principal officers and the departure of a previous officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation:
- Stock Options Granted: 100,000 shares to Joanne M. Protano and 125,000 shares to Kristin C. Schuhwerk.
- Exercise Price: $0.451 per share (closing price on December 17, 2007).
- Vesting Schedule: Equal annual installments over three years.
Material Changes
The primary material change is the transition of the Chief Financial Officer role:
- Appointment: Joanne M. Protano was appointed Vice President, Chief Financial Officer, and Treasurer.
- Appointment: Kristin C. Schuhwerk was appointed Vice President of Clinical Development, Operations.
- Departure: George Vaughn, who served as CFO on a consulting basis since 2005, was succeeded by Ms. Protano. Mr. Vaughn will continue to provide consulting services to the Company.
Management Commentary and Risks
The filing provides biographical details for the new appointees:
- Joanne M. Protano: Previously served as Senior Director of Finance and Controller since June 2006. Former experience includes CFO roles at Ascential Software and audit management at Deloitte and Touche LLP.
- Kristin C. Schuhwerk: Previously served as Director/Senior Director of Operations since July 2005. Former experience includes clinical development roles at Antigenics, Inc., Boston University Medical Center, and AstraZeneca.
The filing does not contain specific guidance, outlook, or discussion of risks and contingencies beyond the standard executive transition.
Investor Verification Checklist
- Verify the correct registrant name is Novelos Therapeutics, Inc., not Cellectar Biosciences, Inc.
- Confirm the stock price of $0.451 on the Over the Counter Bulletin Board as of December 17, 2007.
- Review the specific terms of the consulting agreement continuing with George Vaughn.
- Check subsequent filings for the impact of these leadership changes on clinical development timelines.